Emcure says court should dismiss COVID vaccine secrets suit
17-05-2022
Generic Emcure stole COVID-19 vaccine trade secrets, lawsuit claims
22-03-2022
Amneal obtains non-infringement finding in Sensipar case
01-08-2018
tumsasedgars / iStockphoto.com
Amgen has accused India-based Emcure Pharmaceuticals of patent infringement, in a bid to protect its drug Sensipar (cinacalcet hydrochloride).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Amgen, Heritage Pharmaceuticals, Emcure Pharmaceuticals, generics, ANDA, FDA, patent infringement, Sensipar
